View this video below to understand the market opportunity Anteo Diagnostics has if successful in moving into a commercial partnership with BBI Solutions who Anteo signed a HOT Agreement with on November 2013.
BBI Solutions are a subsidiary company of the major global healthcare player ALERE (NYSE:ALR)
Alere is the global leader in the rapid test point of care market with close to $3 billion in annual sales.
BBI Solutions supply ALERE with the gold nanoparticles that are needed for every one of these Lateral Flow tests.
In my opinion Mixngo will become a component of these tests and Anteo Diagnostics will receive a royalty for every test sold globally.